Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-18. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
== Biology == The 7kDa proteins are universally found in Sulfolobus, where two copies (Sul7d, Sul7e) are present as separate genes. The proteins are usually named after the species, e.g. Sso7d for the 7d of S. solfataricus and Sac7e for the 7e of S. acidocaldarius. Sul7a and Sul7b are truncated versions of 7d. "Sso7c" does not appear to be a member of this family. S. tokodaii is unusual in that the two copies only differ by one nucleotide and produce the same protein, so its version is simply called Sto7. Across Sulfolobales, Acidianus, Metallosphaera, and "Candidatus Aramenus" also encode a 7kDa DNA-binding protein, named according to the genus name or the species name in an analogous fashion. Each genome may carry anywhere from 1 to 3 versions of the protein.
The lowest possible energy state for a given quantum mechanical system, at which the Gibbs energy is actually or theoretically minimized. Whatever energy remains in the system in its ground state is called the zero-point energy. Contrast excited state.
Using stem-cell-derived GABAergic and glutamatergic neurons, as well as human APOE knock-in mice, researchers find that APOE2 neurons show lower DNA damage and greater resistance to genotoxic-stress-induced cellular senescence than APOE4 neurons, suggesting a possible mechanism for APOE2's association with reduced Alzheimer's disease risk. 11 May – A preprint reports the discovery of Ross 318 b, a candidate temperate super-Earth orbiting within the habitable zone of the nearby red dwarf Ross 318. Detected using radial velocity measurements from CARMENES and HIRES, the planet has a 39.6-day orbit, a minimum mass of 6.21 Earth masses, and shows no detectable transit in TESS photometry. 12 May – A study published in Frontiers in Earth Science reports isotopic evidence from helium and carbon in hydrothermal fluids from Zambia's Kafue Rift, suggesting early-stage rifting in the proposed Southwestern Rift of Africa. The findings indicate mantle-derived fluids reaching the surface and may support the existence of an emerging plate boundary capable of future continental separation. 26 May – A preprint reports the atomically precise mechanosynthesis of carbon structures on hydrogenated silicon using inverted-mode scanning tunneling microscopy (STM). Researchers demonstrate controlled donation of C2 units to pre-patterned reactive sites, repeated placement of carbon units, and stepwise formation of polyyne-like carbon chains through successive C–C bond formation, suggesting a possible route toward programmable atomically precise fabrication.
== Applications == Quantitative/qualitative analysis of collective cell migration under changeable experimental conditions. Analysis of cell-matrix and cell-cell interactions with respect to cell migration. High-throughput screens for: Cancer cell migration genes Small molecules Drug discovery
Sources: en.wikipedia.org
DCI John Caldwell, an off duty Police Service of Northern Ireland officer, is injured in Omagh after being shot by suspected New IRA gunman. 23 February Labour leader Sir Keir Starmer outlines the five key issues that his party will focus on during the run up to the 2024 general election: higher economic growth, clean energy, improving the NHS, reforming the justice system, and raising education standards. Environment Secretary Thérèse Coffey, commenting on the vegetable shortage, tells MPs "we anticipate the situation will last about another two to four weeks". Three men are arrested in relation to the previous evening's shooting of DCI John Caldwell. 24 February The British Medical Association announces that junior doctors in England will begin a three-day strike on 13 March. An earthquake measuring 3.7 magnitude strikes Brynmawr, Blaenau Gwent at 11.59pm. COVID-19 in the UK: Office for National Statistics data for the week up to 14 February indicates COVID-19 cases continued to rise in England, Scotland and Wales, but remained uncertain in Northern Ireland. In England, the estimated number of people testing positive for COVID-19 was 1,223,000 (or 2.18% of the population and around 1 in 45 people). 27 February New Transgender Policy Guidance for England and Wales came into force on 27 February 2023 under which transgender women offenders would no longer be housed in women's prisons if they had male genitalia or had committed sex crimes.
=== Cancer === Ang has a prominent role in the pathology of cancer due to its functions in angiogenesis and cell survival. Since Ang possesses angiogenic activity, it makes Ang a possible candidate in therapeutic treatments of cancer. Studies of Ang and tumor relationships provide evidence for a connection between the two. The translocation of Ang to the nucleus causes an upregulation of transcriptional rRNA, while knockdown strains of Ang cause downregulation. The presence of Ang inhibitors that block translocation resulted in a decrease of tumor growth and overall angiogenesis. HeLa cells translocate Ang to the nucleus independent of cell density. In human umbilical vein endothelial cells (HUVECs), translocation of Ang to the nucleus stops after cells reach a specific density, while in HeLa cells translocation continued past that point. Inhibition of Ang affects the ability of HeLa cells to proliferate, which proposes an effective target for possible therapies.
=== Theory of cellular division: S. Rosetta === Work by Fairclough, Dayel and King suggests that S. Rosetta can exist in either single-cellular form or in colonies of 4-50 cells, which arrange themselves in tight knit packs of spheres. This was established by performing an experiment involving the introduction of prey bacterium Algoriphagus species to a sample of uni-celled S. Rosetta organism and monitored the activity for 12 hours. Results of this study demonstrated that cell colonies were formed through cell-division of the initial solitary S. Rosetta cell rather than by cell aggregation. Further studies to support the theory of cell-proliferation were done by introducing then removing the drug aphidicolin which serves to block cell-division. When the drug was introduced, cell division stopped and colony formation resulted through cell-cell aggregation. When the drug was removed, cell-division dominated once again.
Sources: en.wikipedia.org
=== Cysteine === The genes required for the synthesis of cysteine are coded for on the cys regulon. The integration of sulfur is positively regulated by CysB. Effective inducers of this regulon are N-acetyl-serine (NAS) and very small amounts of reduced sulfur. CysB functions by binding to DNA half sites on the cys regulon. These half sites differ in quantity and arrangement depending on the promoter of interest. There is however one half site that is conserved. It lies just upstream of the -35 site of the promoter. There are also multiple accessory sites depending on the promoter. In the absence of the inducer, NAS, CysB will bind the DNA and cover many of the accessory half sites. Without the accessory half sites the regulon cannot be transcribed and cysteine will not be produced. It is believed that the presence of NAS causes CysB to undergo a conformational change. This conformational change allows CysB to bind properly to all the half sites and causes the recruitment of the RNA polymerase. The RNA polymerase will then transcribe the cys regulon and cysteine will be produced. Further regulation is required for this pathway, however. CysB can down regulate its own transcription by binding to its own DNA sequence and blocking the RNA polymerase. In this case NAS will act to disallow the binding of CysB to its own DNA sequence. OAS is a precursor of NAS, cysteine itself can inhibit CysE which functions to create OAS. Without the necessary OAS, NAS will not be produced and cysteine will not be produced. There are two other negative regulators of cysteine.
It's possible that hackers have gotten into administrative computer systems of utility companies, but says those aren't linked to the equipment controlling the grid, at least not in developed countries. [Schmidt] has never heard that the grid itself has been hacked. In June 2019, Russia said that its electrical grid has been under cyber-attack by the United States. The New York Times reported that American hackers from the United States Cyber Command planted malware potentially capable of disrupting the Russian electrical grid.
In recent years the Microfluidizer method has gained popularity in cell disruption due to its ease of use and efficiency at disrupting many different kinds of cells. The Microfluidizer technology was licensed from a company called Arthur D. Little and was first developed and utilized in the 1980s, initially starting as a tool for liposome creation. It has since been used in other applications such as cell disruption nanoemulsions, and solid particle size reduction, among others. By using microchannels with fixed geometry, and an intensifier pump, high shear rates are generated that rupture the cells. This method of cell lysis can yield breakage of over 90% of E. coli cells. Many proteins are extremely temperature-sensitive, and in many cases can start to denature at temperatures of only 4 degrees Celsius. Within the microchannels, temperatures exceed 4 degrees Celsius, but the machine is designed to cool quickly so that the time the cells are exposed to elevated temperatures is extremely short (residence time 25 ms-40 ms). Because of this effective temperature control, the Microfluidizer yields higher levels of active proteins and enzymes than other mechanical methods when the proteins are temperature-sensitive. Viscosity changes are also often observed when disrupting cells. If the cell suspension viscosity is high, it can make downstream handling—such as filtration and accurate pipetting—quite difficult. The viscosity changes observed with a Microfluidizer are relatively low, and decreases with further additional passes through the machine.
6 – he won against Oscar Otte, Roman Safiullin, Laslo Đere, Kei Nishikori and Alejandro Davidovich Fokina. In the semifinal, he played Stefanos Tsitsipas, to whom he lost after a 5-set battle. Zverev's first appearance on grass started with a tournament at home in Halle – he lost in the second round to the eventual tournament winner Ugo Humbert. At Wimbledon, seeded No. 4, he equaled his best achievement at the tournament to date – reaching the fourth round for a second time. Along the way he defeated Tallon Griekspoor, Tennys Sandgren and Taylor Fritz. He was defeated in the fourth round by Félix Auger-Aliassime in five sets. Following this run he returned to the top 5 after 2 years on 12 July 2021. At the Olympics, Zverev beat Yen-hsun Lu, Daniel Elahi Galán, Nikoloz Basilashvili and Jérémy Chardy to reach the semifinals. In the semifinals, despite being a set and a break down against world No. 1 Novak Djokovic, Zverev rallied to break back and won eight games in a row on his way to win in three sets. He defeated Karen Khachanov in straight sets in the final to claim the Olympic gold medal. Zverev became the first German man to win a gold medal in singles and the first to win a medal since Tommy Haas won his silver medal at the 2000 Sydney Olympics. Following the Olympics, Zverev reached his second Masters 1000 final of the year at the 2021 Western & Southern Open after defeating Lloyd Harris, Guido Pella, Casper Ruud and Stefanos Tsitsipas after a close three-set battle in the semifinal. Zverev had not won a match at the tournament in six prior appearances.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.